Elanco Animal Health (NYSE:ELAN) Price Target Raised to $31.00

Elanco Animal Health (NYSE:ELAN) had its price target boosted by Citigroup from $30.00 to $31.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Citigroup’s price target would indicate a potential upside of 28.82% from the stock’s previous close.

A number of other research analysts have also recently commented on the stock. JPMorgan Chase & Co. raised their price target on shares of Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday. KeyCorp raised their target price on Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Wall Street Zen lowered Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 18th. Piper Sandler upgraded Elanco Animal Health from a “neutral” rating to an “overweight” rating and upped their price target for the company from $24.00 to $30.00 in a research report on Thursday, January 22nd. Finally, Weiss Ratings upgraded Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, April 27th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.20.

Elanco Animal Health Stock Performance

Shares of ELAN traded down $2.12 during trading hours on Thursday, reaching $24.07. 11,810,339 shares of the company traded hands, compared to its average volume of 5,067,905. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.08 and a current ratio of 2.17. The stock’s fifty day moving average is $23.85 and its 200 day moving average is $23.33. Elanco Animal Health has a 1-year low of $11.83 and a 1-year high of $27.72. The stock has a market cap of $11.96 billion, a P/E ratio of -50.13, a price-to-earnings-growth ratio of 2.93 and a beta of 1.69.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.06. The firm had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The company’s quarterly revenue was up 14.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.37 earnings per share. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Equities research analysts anticipate that Elanco Animal Health will post 1.03 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Elanco Animal Health

A number of large investors have recently modified their holdings of the stock. Parallel Advisors LLC grew its position in shares of Elanco Animal Health by 5.9% during the 4th quarter. Parallel Advisors LLC now owns 7,060 shares of the company’s stock worth $160,000 after buying an additional 392 shares during the period. Lazard Asset Management LLC raised its position in shares of Elanco Animal Health by 0.6% in the 4th quarter. Lazard Asset Management LLC now owns 72,065 shares of the company’s stock valued at $1,631,000 after acquiring an additional 425 shares during the period. Northwestern Mutual Investment Management Company LLC raised its position in shares of Elanco Animal Health by 0.4% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 111,166 shares of the company’s stock valued at $2,516,000 after acquiring an additional 428 shares during the period. Meeder Advisory Services Inc. boosted its stake in Elanco Animal Health by 4.8% during the 4th quarter. Meeder Advisory Services Inc. now owns 11,235 shares of the company’s stock worth $254,000 after acquiring an additional 510 shares during the last quarter. Finally, Bessemer Group Inc. boosted its stake in Elanco Animal Health by 33.2% during the 1st quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock worth $50,000 after acquiring an additional 525 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Elanco Animal Health

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Q1 beat and upgraded full‑year targets: Elanco reported Q1 revenue of $1.371B (+15% y/y) and adjusted EPS of $0.40, above consensus, and raised FY 2026 guidance for revenue, adjusted EBITDA and adjusted EPS while improving year‑end net leverage goals. This is the primary fundamental positive supporting the stock. PR Newswire: Q1 Results
• Positive Sentiment: Product momentum and approvals: Elanco highlighted product wins (Negasunt Powder and Tanidil emergency use authorizations) cited as drivers of near‑term revenue momentum. Investors view product approvals as supportive for innovation revenue growth. Benzinga: Product Momentum
• Positive Sentiment: Analyst upgrade: JPMorgan raised its price target to $30 and moved Elanco to an “overweight” rating, signaling a ~25% upside from the recent price and potentially supporting further analyst-driven buying. Benzinga: JPMorgan PT Raise
• Neutral Sentiment: Full disclosure materials available: The company posted its earnings slide deck and the full earnings call transcript for deeper investor review — useful for modeling and verifying management commentary. Earnings Presentation Earnings Call Transcript
• Negative Sentiment: Near‑term guide miss and investor focus on Q2: Elanco set Q2 EPS guidance of $0.250–0.285, below the consensus figure cited in coverage (~$0.290). That softer near‑term guide appears to be a key reason shares fell despite the beat and FY raise. Zacks: Q1 Beat & Guidance
• Negative Sentiment: Profitability and leverage remain watchpoints: The company still shows a negative net margin and leveraged balance sheet (net leverage ~3.5x now), which keeps some investors cautious despite improved targets. Market participants may be trimming positions on these structural risks. MarketBeat: Financial Snapshot

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.